Hillevax Inc is a pharmaceutical company that caught the eye of investors with its recent IPO. It’s an American startup headquartered in Boston, Massachusetts, It’s a solid and established enterprise that specializes in developing and commercializing novel vaccines. If this is the first time you’re hearing about the newly formed publicly-traded company, here are twenty things you probably didn’t know about Hillevax to bring you up to speed.
1. Hillevax Inc is a brand new company
Crunchbase confirms that Hillevax Inc is a new company that is still in its infant stages of development. It launched its operations in 2021, making it less than one year old. Although rare, it’s already held its initial public offering and is a publicly-traded company, offering its shares of stock to the public as an investment option. Hillevax is listed under the pharmaceutical, biopharma, and biotechnology industries.
2. Interest in Hillevax is growing exponentially
The analytics report for the Hillevax Inc website shows that the volume of web traffic to the site is growing at an exponential rate. The report details the past thirty days, tracking the number of people who have visited the website. One hundred percent of the visitors are from the United States. The report confirms that 10,642 people visited the website giving HilleVax’s website a ranking of number 2,0060,064 of the millions of websites registered on the world wide web. The number of monthly visits has grown by an astronomical 739.94 percent over the past month.
3. Hillevax Inc has one founder
The founder of Hillevax inc is Davis Sox. He also serves as the CBO and CFO of the company. He is a serial entrepreneur who has founded four organizations. he currently serves on one board of directors in an advisory role. He is the sole executive officer listed under the company’s executive division but he is supported by a larger team of managers and staff in leadership positions.
4. Hillevax Inc lists a six-member support team of managers
David Socks is the CFO and CBO of Hillevax Inc, but he isn’t carrying the weight of the company by himself. He is supported by a small management team. Jinrong Zhang is a clinical operation/clinical serology senior scientist. Kristin Yannetti is an executive assistant. Mark Lyons is the director of analytical development. Paul Bavier is the general counsel and serves as a chief administrative officer. Paul Troccolo is a principal scientist of immunology and potency. Ryan Thurston is a director of manufacturing of science & technology.
5. Hillevax was venture funded before its IPO
Hillevax participated in one round of venture capital fundraising before it filed for its initial public offering. HilleVax raised a total of $135 million in its unknown Venture Series round that closed on September 8, 2021. Hillevax was supported by three investors including Sahsen Ventures, Catalys Pacific, and Frazier Healthcare Partners. The business went public shortly after its first and only investment round.
6. Hillevax has a strong executive leadership team
Hillevax is led by its chief operating officer, president, and Chair Robert Hershberg, MD. Doctor Hershberg is a venture partner with Frazier Healthcare Partners who worked with the company as an entrepreneur in residence and executive for 14 years. He has an impressive and long history of executive positions within the pharmaceutical industry. He co-founded a company called VentiRx and also worked for Dendreon Corporation, Celgene, and Corixa. He earned his Ph.D. at the Salk Institute for Biological Studies. Astrid Borkowski MD is the chief medical officer. Aditya Kohli Ph.D. is the chief operating officer. Paul Bavier JD is the general council, etc. Anju Chatterji Ph.D. is the senior vice president of technical operations. Kaia Agarwals is the senior vice president of regulatory affairs.
7. Hillevax has a nine-member board of directors
The board of directors for Hillevax Inc has five members. Shelley Chu, MD, Ph.D. is a partner at Lightspeed Ventures. She serves on numerous boards of directors in advisory roles. Dr. Gary Dubi is the president of Takeda’s Global Vaccine Business. He brings over thirty years of experience in the pharmaceutical business in vaccine research and development to the group. Julie Gerberding is the chief patient officer and executive vice president of population health and sustainability at Merck. Before that, she was the president of vaccines at the company and the forever director of the United States Centers for Disease Control. Jeri Hilleman is the former CFO of Symtyx Technologies and Chair of Omada Health. Aditya Kohli is the COO of HilleVax and a venture partner with Frazier Healthcare Partners. Dr. Jaime Sepulveda is a Haile T. Debas Distinguished Professor of Global Health and the executive director of UCSF for Global Health Services. Susan Silbermann is a former Global President for Emerging Markets at Pfizer and Pfizer Vaccines.
8. Other investors have a stake in Hillevax
Other investors not yet mentioned have invested in Hillevax Inc. They include RA Capital, Deerfield Advancing Healthcare, Abingworth, Perceptive Advisors, Samsara Biocapital, Franklin Templeton Investments, BFV Partners LP, Qiming Venture Partners, Lightspeed, Greenspring Associates, and the Richard King Mellon Foundation. We gathered this information from the Hillevax, Inc website.
9. Hillevax Inc has a strong candidate drug in the pipeline
The strongest candidate drug in the Hillevax Inc pipeline is its initial program titled HIL-214. It’s a vaccine based on a virus-like particle that is under development to prevent gastroenteritis caused by the Norovirus. The virus can be deadly in some people, and severely sicken others. Studies show promise in the efficacy of the drug which is generally well-tolerated in people of all ages from 6-weeks to 102 years old. The studies are in the 11b phase of development and clinical trials with humans in the aforementioned age groups
10. Hillevax offers numerous publications for professionals and the public
Hillevax Inc offers a variety of publications to help educate the public and professionals in healthcare. It publishes the results of its research studies and clinical trials to share information about the results achieved. Some of the publications include “Norovirus Vaccine Against Experimental Human Norwalk Virus Illness,” “Efficacy of Intramuscular Bivalent Norovirus: G1/GII Virus-like Particle Vaccine Candidate in Healthy US Adults,” and several others.
11. Hillevax Inc closed its IPO on May 3, 2022
Globe-News Wire reports that Hillevax Inc. closed its initial public offering on May 3, 2022. The new company offered 13,529,750 shares of common stock in the offering, including purchase options of 1,764,750 for its underwriters as additional shares. The initial offering price of shares was $17.00. The venture raised funds of $230 million. Hillevax is listed on the Nasdaq Global Select Market under the symbol HLVX.
12. Hillevax Inc is a small publicly-traded company
LinkedIn confirms that Hillevax is a small company with a barebones workforce. The number of staff members currently listed is just thirty-four. We checked the credentials of each of the workers and learned that they only hire people who bring years of experience to the positions. They run a tight staff and maintain efficiency in using the company’s financial resources.
13. Hillevax Inc is currently hiring
Hillevax Inc is seeking to expand its current workforce and shore up its operations. The company posted twelve new position openings at the company. Most of the jobs are listed for the headquarters’ location in Boston, Massachusetts. A few of them are remote positions open to anyone in the United States who is otherwise qualified. The new positions are equal to a one-third growth in the size of the Hillevax Inc workforce.
14. Hillevax Inc is fighting on a new front
YRT News reports that Covid cases are beginning to decline, but there is a new threat on the horizon. The number of Norovirus infections abound across the globe. Most people who come down with a Norovirus infection recover from the infection within a few days, but some people are not that fortunate. It’s resulted in the need for a vaccine to help prevent the spread of the virus or at least curb the number of incidences. Hillevax and other biotech companies are beginning to turn their attention to Norovirus.
15. Hillevax is the result of a collaborative effort
Hillevax was created from the joint efforts of Pharmaceutical Takeda and Frazier Healths Partners. They’re two of the larger names in the healthcare industry. Some people assume that because the two companies helped to encourage the launch of Hillevax, the company is more stable because of its backing. In part that is true, but the support may not be enough to promise a healthy return on stock investments in the new organization. It hasn’t been on the public stock exchange for long enough to draw any meaningful inclusions just yet.
16. HilleVax offers a strong potential impact on society
Benzinga confirms that Hillevax’s development of an effective norovirus vaccine can help people to avoid getting sick or dying from the disease. The current statistics show that approximately 700 million people come down with the infection each year. Out of that number, approximately 200,000 people die from the disease. The potential exists to decrease the number of illnesses and deaths, creating a more robust population that is resistant to this common sickness.
17. Hillevax Inc shows promise for easing economic disruption
Many of us don’t stop to think about the impact that a common virus can have on the economics of the world. Hillevax inc seeks to lessen the global annual expense caused by Norovirus, which is approximately $4.2 billion in estimated direct health costs. This information is supported by data shared by the National Institutes of Health with children five years and younger costing society $39.8 billion in healthcare costs. Additionally, about $60.4 billion is the cost of worker displacement due to Norovirus infections.
18. Hillevax Inc has a short but solid financial history
Hillevax Inc has no compelling financial difficulties, although it’s a relatively new company. It exists in a field with a high demand for medical treatments and vaccines. Hillevax Inc has made significant clinical progress, but it has also received millions in financial support from its investors and IPO participants. The potential for rewards is high for Hillevax, and it comes from a solid position at this point in its development. Although the firm lost more money than the investors have put into it, the excitement lies in the potential for its candidate vaccine to make a difference in the world. It’s nothing new for companies to experience loss in their first phases of development. The positive aspect is strong investor support during its infancy stages.
19. Hillevax Inc is still a gamble
If you’re considering an investment in Hillevax Inc stock, it’s essential to remember that any stock investment is taking a calculated risk. Not enough is known about the company to make a sound judgment of how it will perform in the months and years ahead. There is no performance history and little financial history to base calculations upon. Most of the hype surrounding the potential of Hillevac lies in extraneous factors with the medical need for a vaccine to prevent Norovirus infection. Although the company makes a good case, there may be hesitancy from a public that has been overwhelmed with questions over the safety and effectiveness of new vaccines.
20. Hillevax is a company to keep your eye on
If you’re considering adding Hillevax stock to your investment portfolio, it may be wise to watch the stock for a few quarters to see how it performs in its new role as a publicly-traded company. It’s helpful to have an idea of the current trends about a stock before jumping in with an investment. Hillevax doesn’t have much data to offer yet, but it will in the months to come. It’s always wise to consult with your financial advisor before making a decision.